Enjoy complimentary customisation on priority with our Enterprise License!
The mycoplasma testing market size is estimated to grow by USD 645.51 million at a CAGR of 12.25% between 2022 and 2027.
There is increasing adoption of real-time mycoplasma testing across the hospital sectors. One of the main advantages of real-time mycoplasma testing is that it quickly offers the presence of mycoplasma contamination in biological products, unlike traditional testing which requires days or months to deliver the mycoplasma test results. Additionally, there is an increasing focus by several market players on the development of real-time mycoplasma testing products. For instance, MycoSEQ Mycoplasma Detection System is developed by Thermo Fisher Scientific, which offers test results in hours and is integrated with real-time PCR assays and systems along with software with optimized PrepSEQ sample preparation reagent. Furthermore, there is a growing popularity for real-time mycoplasma testing products in cell lines, cell banks, pharmaceutical and biotechnology companies, CROs, research institutes, and harvest media which is expected to positively impact the market growth.
Technavio has segmented the market into End-user, Product, and Geography.
It also includes an in-depth analysis of drivers, trends, and challenges. Our report examines historic data from 2017 to 2021, besides analyzing the current market scenario.
To learn more about this report, Request Free Sample
The pharmaceutical and biotechnology companies segment is estimated to witness significant growth during the forecast period. One of the major causes of batch failure in biopharmaceutical production is microbial contamination, such as mycoplasma contamination. These contaminations can result in significant loss of time and material, leading to loss of revenue to the biopharmaceutical companies. Hence, mycoplasma testing is vital for these companies at various stages in the manufacturing process.
Get a glance at the market contribution of various segments View a PDF Sample
The pharmaceutical and biotechnology companies segment was the largest segment and was valued at USD 200.92 million in 2017. Mycoplasma testing products are widely used to identify the presence of microbes such as mycoplasma detected in the early stage of the production process which can significantly reduce the loss incurred by biotechnology and pharmaceutical companies. Additionally, there is increasing support from the government which is resulting in growing R&D activities in drug development by biopharmaceutical companies. Hence, such factors are expected to drive the growth of this segment which in turn will drive the global mycoplasma testing market growth during the forecast period.
The consumables segment is widely used for identifying mycoplasma contamination such as kits and reagents including PCR assays, nucleic acid detection kits, staining materials, elimination kits and reagents, standards, and controls. The kits and reagents are frequently used in mycoplasma testing and need regular purchases by pharmaceutical companies and biomedical research organizations. Several prominent market players such as InvivoGen manufactures test kit such as essays for the visual detection of mycoplasma in the cell culture. Hence, such factors are expected to fuel the growth of this segment which in turn will drive the global mycoplasma testing market growth during the forecast period.
The mycoplasma testing systems are mainly used to identify mycoplasma contamination, especially in cell cultures, as it is a widespread and frequent problem in a wide variety of cell cultures. The presence or absence of mycoplasma contaminants is identified by these systems. There is an increasing demand for these systems in pharmaceutical and biotechnology companies, cell banks, academic research institutes, and CROs due to their ability to quickly identify mycoplasma within a few hours. Furthermore, several prominent players are manufacturing real-time mycoplasma detection systems due to their high adoption. Hence, such factors are expected to fuel the growth of this segment which in turn will drive the global mycoplasma testing market growth during the forecast period.
For more insights about the market share of various regions View PDF Sample now!
North America is estimated to contribute 40% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers that will shape the market during the forecast period. One of the main factors which are significantly contributing to the growth of the global mycoplasma testing market in North America is due to the rising number of life science researchers and the presence of life science research firms and laboratories such as the Charles River Laboratories and Gibraltar Laboratories. Some of the key end-users which use mycoplasma testing for controlling mycoplasma contamination are biotechnology, biological, and pharmaceutical companies.
Therefore, several laboratories perform mycoplasma testing which helps the companies to avoid mycoplasma contamination. Factors such as increasing focus on drug and vaccine discovery and development, recent advances in biotechnology and pharmaceutical research, and the presence of several prominent market players in the region offering a wide range of mycoplasma testing products are significantly fuelling the market growth in the region during the forecast period.
In 2020, during the COVID-19 pandemic, the growth of global mycoplasma testing market witnessed significant growth as the number of co-infection cases increased significantly in North America, resulting in increased demand for mycoplasma testing However, in 2021, the initiation of large-scale vaccination drives?has lifted the lockdown and travel restrictions, decrease in demand for mycoplasma testing due to decrease in COVID cases. But the continuous development in biotechnology in the region is expected to drive the market during the forecast period.
Buy Now Full Report and Discover More
Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market. The report also includes detailed analyses of the competitive landscape of the market and information about 20 market companies, including:
Agilent Technologies Inc: The company offers mycoplasma testing products such as MycoSensor qPCR assay kits.
Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.
There are multiple factors influencing market growth. Our researchers analyzed the data with 2022 as the base year, along with the key drivers, trends, and challenges.
One of the key factors driving the global mycoplasma testing market growth is the growing geriatric population. One of the rapidly growing segments in the global population is the geriatric segment. According to the estimates by The World Bank Group and the NIH, the proportion of the geriatric population in the global population is expected to grow from 8.48% in 2016 to approximately 17% by 2050. The main reason is the advancement in several healthcare technologies which resulted in the availability of more efficient treatment options leading to increased life expectancy.
Additionally, the increase in median age due to growing life expectancy resulted in the growth in the elderly adult population. Factors such as the shift in causes of death from fatal acute infections to chronic conditions such as arthritis, diabetes, high cholesterol, and hypertension, especially due to changing lifestyle is leading to longevity. Additionally, several advancements in medicine have resulted in declining cases of disability. Hence, factors are expected to drive market growth during the forecast period.
A key factor shaping the global mycoplasma testing market growth is the increasing initiatives for rapid diagnostics of infectious diseases. There is a significant increase in government funding to increase access to diagnostics via several technological innovations. Additionally, there is a rise in focus by several governments in developed and developing countries on enhancing access to mycoplasma testing products.
Furthermore, several market players in the global mycoplasma testing market are developing high-quality diagnostic technologies for chronic and infectious diseases but these are not accessible as well as affordable in some developing economies. As a result, the governments in these countries are undertaking many initiatives to improve access to diagnostics. Additionally, with the help of international organizations such as Unitaid, several developing countries such as Brazil, South Africa, India, Zambia, and China are receiving access to in vitro diagnostic devices at preferential prices. Hence, such factors are expected to drive the global mycoplasma testing market growth during the forecast period.
The high cost of mycoplasma testing products is one of the key challenges hindering market growth. The high cost associated with mycoplasma testing is due to the high price of products such as mycoplasma testing systems, assays, and frequently used consumables such as kits and reagents. The cost highly relies on the level of features provided by these products.
For instance, integrated systems such as the BD FACSMicroCount system provide a versatile and comprehensive solution for the rapid enumeration of microorganisms such as product screening, sterility testing, mycoplasma testing, and probiotic count. Hence, such integrated systems equipped with advanced features are expensive when compared to traditional mycoplasma testing systems. Hence, such factors are expected to hinder the global mycoplasma testing market growth during the forecast period.
Buy Now Full Report and Discover More
The market report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their growth strategies.
Global Mycoplasma Testing Market Customer Landscape
The mycoplasma testing market report forecasts market growth by revenue at global, regional & country levels and provides an analysis of the latest trends and growth opportunities from 2017 to 2027.
Mycoplasma Testing Market Scope |
|
Report Coverage |
Details |
Page number |
170 |
Base year |
2022 |
Historic period |
2017-2021 |
Forecast period |
2023-2027 |
Growth momentum & CAGR |
Accelerate at a CAGR of 12.25% |
Market growth 2023-2027 |
USD 645.51 million |
Market structure |
Fragmented |
YoY growth 2022-2023(%) |
10.36 |
Regional analysis |
North America, Europe, Asia, and Rest of the World (ROW) |
Performing market contribution |
North America at 40% |
Key countries |
US, Canada, UK, Germany, and China |
Competitive landscape |
Leading Vendors, Market Positioning of Vendors, Competitive Strategies, and Industry Risks |
Key companies profiled |
Agilent Technologies Inc., ATCC, Akron Biotechnology LLC, Becton Dickinson and Co., Bio-Techne Corp., Bionique Testing Laboratories Inc., Charles River Laboratories International Inc., DiaSorin SpA, Dilarus GmbH, F. Hoffmann La Roche Ltd., GeneCopoeia Inc., InvivoGen Corp., Lonza Group Ltd., Merck KGaA, Norgen Biotek Corp., PromoCell GmbH, Sartorius AG, ScienCell Research Laboratories Inc., SGS SA, and Thermo Fisher Scientific Inc. |
Market dynamics |
Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, and Market condition analysis for the forecast period. |
Customization purview |
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
View Sample PDF at your Fingertips
We can help! Our analysts can customize this market research report to meet your requirements. Get in touch
Get lifetime access to our
Technavio Insights
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.